Ingredient or product comparison
How FDA Classifies GHK-Cu: Cosmetic vs Drug Determination
FDA does not pre-approve cosmetic ingredients the way it approves drugs. Instead, it applies a two-part test: (1) What is the product's intended use as communicated through labeling, marketing, and consumer perception? (2) Does the product affect the structure
This source-based comparison does not add ratings or recommend a winner.
- FDA does not pre-approve cosmetic ingredients the way it approves drugs. Instead, it applies a two-part test: (1) What is the product's intended use as communicated through labeling, marketing, and consumer perception? (2) Does the product affect the structure or function of the body beyond cleansing, beautifying, or altering appearance?
- GHK-Cu triggers this test immediately because its mechanism of action is well-documented in peer-reviewed literature. The tripeptide binds to copper ions, forming a complex that demonstrates measurable effects on matrix metalloproteinase activity, transforming growth factor-beta signaling, and extracellular matrix remodeling in cultured fibroblasts. These are biological effects. Not merely aesthetic effects.
- FDA's stance: if a product containing GHK-Cu claims to deliver those biological effects, it is a drug. If it claims only to 'improve the appearance of skin texture' or 'support skin hydration,' it remains a cosmetic. The active ingredient is identical; the classification depends on what the brand says it does.
- This is why experienced formulators never use mechanism language in consumer-facing cosmetic labels. A product containing 0.1% GHK-Cu marketed as an 'anti-aging serum that enhances skin radiance' is a cosmetic. The same formulation marketed as 'clinically shown to increase type I collagen deposition by 70% in 8 weeks' is an unapproved new drug requiring pre-market approval, clinical trials, and manufacturing under current Good Manufacturing Practice (cGMP) regulations.
- The copper component introduces an additional consideration. FDA regulates copper as both a nutrient (when ingested) and a cosmetic colorant (when applied topically). GHK-Cu as a copper complex is not classified as a color additive because the copper is bound within the peptide structure, not used as a pigment. However, if the formulation delivers free copper ions. Which can occur if the peptide complex degrades during storage. FDA could reclassify the product based on the presence of an unapproved additive.
- In 2026, the practical enforcement reality is this: FDA does not routinely test cosmetics for GHK-Cu content or review formulations before sale. Enforcement is complaint-driven and claim-triggered. Brands operating in gray zones. Making subtle efficacy claims without crossing into explicit drug language. Often remain undetected until a competitor files a complaint, a consumer reports an adverse event, or the product garners enough market share to attract regulatory attention.